ADC Leadership NJ Bio is a recognized leader in antibody-drug conjugate development and bioconjugation, with ongoing plans for expansion with Lotte Biologics to enhance ADC services and apply bioconjugation processes to production facilities. This creates a strong opportunity to offer end-to-end ADC development and manufacturing, plus related areas such as PROTAC and flow chemistry based process development, to pharma and biotech clients seeking integrated chemistry and biology CRO support.

Global Footprint The company operates from its Princeton headquarters with additional chemistry facilities nearby and maintains a multinational structure including an India subsidiary, enabling multi site programs, nearshore and offshore options, and distributed capabilities to support clinical timelines and supply chain resilience.

Tech Advantage NJ Bio leverages cloud based data tooling and analytics for chemistry and biology projects, and collaborates on high end NMR platform development with JEOL, indicating strong capabilities for structure elucidation, process optimization, and data driven decision making that can accelerate project timelines.

Credible Growth Award winning track record as a best CRO in industry events and a solid revenue range signals credibility and capacity to take on growing programs, including expansion of ADC production capabilities to meet client demand.

End to End Offering integrated chemistry and biology services across ADCs, nucleotide and oligonucleotide synthesis, multi step organic synthesis, PROTAC and flow chemistry based process development positions NJ Bio as a single source for early phase discovery through process development, inviting clients to pursue bundled engagements and long term strategic collaborations.